Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2021 | May 10, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-36467 | |
Entity Registrant Name | RESONANT INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 45-4320930 | |
Entity Address, Address Line One | 10900 Stonelake Blvd, Suite 100, Office 02-130 | |
Entity Address, City or Town | Austin | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 78759 | |
City Area Code | 805 | |
Local Phone Number | 308-9803 | |
Title of 12(b) Security | Common Stock, $0.001 par value | |
Trading Symbol | RESN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 60,423,123 | |
Entity Central Index Key | 0001579910 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS | ||
Cash and cash equivalents | $ 21,589 | $ 24,968 |
Accounts receivable | 315 | 208 |
Prepaid expenses and other current assets | 537 | 511 |
TOTAL CURRENT ASSETS | 22,441 | 25,687 |
PROPERTY AND EQUIPMENT | ||
Property and equipment | 4,992 | 4,892 |
Less: Accumulated depreciation and amortization | (3,520) | (3,309) |
PROPERTY AND EQUIPMENT, NET | 1,472 | 1,583 |
OTHER NONCURRENT ASSETS | ||
Intangibles, net of accumulated amortization of $451 and $516, respectively | 2,291 | 2,119 |
Restricted cash | 105 | 105 |
Goodwill | 852 | 911 |
Operating lease right-of-use assets | 1,857 | 2,012 |
Finance lease right-of-use asset | 191 | 201 |
Other assets | 50 | 112 |
TOTAL OTHER NONCURRENT ASSETS | 5,346 | 5,460 |
TOTAL ASSETS | 29,259 | 32,730 |
CURRENT LIABILITIES | ||
Accounts payable | 1,016 | 982 |
Accrued expenses | 232 | 449 |
Accrued salaries and payroll related expenses | 2,142 | 1,970 |
Deferred revenue | 1,262 | 1,721 |
Operating lease liabilities, current | 662 | 699 |
Financing lease liabilities, current | 39 | 30 |
TOTAL CURRENT LIABILITIES | 5,353 | 5,851 |
LONG-TERM LIABILITIES | ||
Deferred revenue | 33 | 62 |
Operating lease liabilities, net of current portion | 1,461 | 1,589 |
Financing lease liability, net of current portion | 165 | 175 |
TOTAL LIABILITIES | 7,012 | 7,677 |
Commitments and contingencies | ||
STOCKHOLDERS’ EQUITY | ||
Common stock, $0.001 par value, 100,000,000 authorized and 60,201,721 outstanding as of March 31, 2021 and 59,128,356 outstanding as of December 31, 2020 | 60 | 59 |
Preferred stock, $0.001 par value, 3,000,000 authorized and none outstanding as of March 31, 2021 and December 31, 2020 | 0 | 0 |
Additional paid-in capital | 181,891 | 175,813 |
Accumulated other comprehensive income | 25 | 87 |
Accumulated deficit | (159,729) | (150,906) |
TOTAL STOCKHOLDERS’ EQUITY | 22,247 | 25,053 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 29,259 | $ 32,730 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Intangible, accumulated amortization | $ 451 | $ 516 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares outstanding (in shares) | 60,201,721 | 59,128,356 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 3,000,000 | 3,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Income Statement [Abstract] | ||
REVENUES | $ 608 | $ 544 |
OPERATING EXPENSES | ||
Research and development | 5,351 | 5,462 |
Sales, marketing and administration | 4,077 | 3,139 |
TOTAL OPERATING EXPENSES | 9,428 | 8,601 |
NET OPERATING LOSS | (8,820) | (8,057) |
OTHER INCOME (EXPENSE) | ||
Interest and investment income (expense) | (3) | 57 |
Other expense | 0 | (4) |
TOTAL OTHER INCOME (EXPENSE), NET | (3) | 53 |
LOSS BEFORE INCOME TAXES | (8,823) | (8,004) |
Provision for income taxes | 0 | 1 |
NET LOSS | (8,823) | (8,005) |
Foreign currency translation adjustment, net of tax | (62) | 9 |
COMPREHENSIVE LOSS | $ (8,885) | $ (7,996) |
NET LOSS PER SHARE - BASIC (in dollars per share) | $ (0.15) | $ (0.18) |
NET LOSS PER SHARE - DILUTED (in dollars per share) | $ (0.15) | $ (0.18) |
Weighted average shares outstanding — basic (in shares) | 59,775,674 | 43,833,127 |
Weighted average shares outstanding — diluted (in shares) | 59,775,674 | 43,833,127 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income |
Beginning balance (in shares) at Dec. 31, 2019 | 33,156,000 | ||||
Beginning Balance at Dec. 31, 2019 | $ 9,756 | $ 33 | $ 132,214 | $ (122,492) | $ 1 |
Increase (Decrease) in Stockholders' Equity | |||||
Vesting of restricted stock units (in shares) | 378,000 | ||||
Stock-based compensation | 1,338 | 1,338 | |||
Sales of common stock, net of offering costs (in shares) | 19,167,000 | ||||
Sale of common stock net of offering costs | 26,460 | $ 19 | 26,441 | ||
Net loss | (8,005) | (8,005) | |||
Foreign currency translation adjustments, net of tax | 9 | 9 | |||
Ending balance (in shares) at Mar. 31, 2020 | 52,701,000 | ||||
Ending Balance at Mar. 31, 2020 | 29,558 | $ 52 | 159,993 | (130,497) | 10 |
Beginning balance (in shares) at Dec. 31, 2019 | 33,156,000 | ||||
Beginning Balance at Dec. 31, 2019 | $ 9,756 | $ 33 | 132,214 | (122,492) | 1 |
Ending balance (in shares) at Dec. 31, 2020 | 59,128,356 | 59,128,000 | |||
Ending Balance at Dec. 31, 2020 | $ 25,053 | $ 59 | 175,813 | (150,906) | 87 |
Increase (Decrease) in Stockholders' Equity | |||||
Vesting of restricted stock units (in shares) | 195,000 | ||||
Stock-based compensation | 1,694 | 1,694 | |||
Sales of common stock, net of offering costs (in shares) | 774,000 | ||||
Sale of common stock net of offering costs | 4,094 | $ 1 | 4,093 | ||
Exercises of stock options (in shares) | 104,000 | ||||
Exercise of stock options | 291 | 291 | |||
Net loss | (8,823) | (8,823) | |||
Foreign currency translation adjustments, net of tax | $ (62) | (62) | |||
Ending balance (in shares) at Mar. 31, 2021 | 60,201,721 | 60,201,000 | |||
Ending Balance at Mar. 31, 2021 | $ 22,247 | $ 60 | $ 181,891 | $ (159,729) | $ 25 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | Mar. 31, 2021 | Dec. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES | |||||
Net Loss | $ (8,823) | $ (8,005) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation and amortization | 235 | 258 | |||
Stock-based compensation | 2,147 | 1,379 | |||
Patent write-off | 6 | 0 | |||
Operating lease right-of-use asset amortization | 155 | 147 | |||
Finance lease right-of-use asset amortization | 10 | 0 | |||
Changes in assets and liabilities: | |||||
Accounts Receivable | (107) | 73 | |||
Prepaid expenses and other current assets | (26) | (156) | |||
Other assets | 62 | 0 | |||
Accounts payable | 281 | 51 | |||
Accrued expenses | (149) | (256) | |||
Accrued salaries and payroll related expenses | (281) | (308) | |||
Operating lease liabilities | (165) | (148) | |||
Deferred revenue | (488) | (262) | |||
Net cash used in operating activities | (7,143) | (7,227) | |||
CASH FLOWS FROM INVESTING ACTIVITIES | |||||
Purchase of property and equipment | (294) | (200) | |||
Expenditures for patents | (328) | (132) | |||
Net cash used in investing activities | (622) | (332) | |||
CASH FLOWS FROM FINANCING ACTIVITIES | |||||
Gross proceeds from the sale of common stock | 4,220 | 28,750 | |||
Offering costs in connection with sale of common stock | (126) | (2,290) | |||
Proceeds from exercise of stock options | 291 | 0 | |||
Net cash provided by financing activities | 4,385 | 26,460 | |||
Effects of exchange rates on cash, cash equivalents and restricted cash | 1 | 0 | |||
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (3,379) | 18,901 | |||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period | 25,073 | 10,838 | $ 10,838 | ||
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period | 21,694 | 29,739 | 25,073 | ||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |||||
Taxes Paid | 1 | 1 | |||
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES | |||||
Common stock issued in settlement of accrued salaries and payroll related expenses | 0 | 280 | |||
Property and equipment included in accounts payable | 71 | 142 | |||
Property and equipment included in accrued expenses | 0 | 46 | |||
Patents included in accounts payable | 95 | 84 | |||
Finance lease included in accounts payable | 4 | 0 | |||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | |||||
Cash and cash equivalents | $ 21,589 | $ 24,968 | |||
Restricted cash | 105 | 105 | |||
Total cash, cash equivalents and restricted cash | $ 25,073 | $ 29,739 | $ 25,073 | $ 21,694 | $ 25,073 |
ORGANIZATION AND DESCRIPTION OF
ORGANIZATION AND DESCRIPTION OF BUSINESS | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
ORGANIZATION AND DESCRIPTION OF BUSINESS | ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Resonant Inc. is a late-stage development company located in Austin, Texas, with offices in Goleta, California, Burlingame, California, and Anyang, South Korea. We were incorporated in Delaware in January 2012 as a wholly owned subsidiary of Superconductor Technologies Inc., or STI. Resonant LLC, a limited liability company, was formed in California in May 2012. We changed our form of ownership from a limited liability company to a corporation in an exchange transaction in June 2013, when we commenced business. We are the successor of Resonant LLC. We completed our initial public offering, or IPO, on May 29, 2014. On July 6, 2016 we acquired all of the issued and outstanding capital stock of GVR Trade S.A, or GVR. GVR, located in Switzerland, is a wholly owned subsidiary of Resonant Inc. The company operates in one market and segment, the radio frequency design industry. The innovative software platform we continue to develop is based on fundamentally new technology that we call Infinite Synthesized Networks ® , or ISN ® , to configure and connect resonators, the building blocks of RF filters. Currently, we are leveraging ISN ® to develop designs targeted for either the Surface Acoustic Wave (SAW) or Temperature Compensated, Surface Acoustic Wave (TC-SAW) manufacturing processes. We also enabled ISN ® for BAW designs, which has resulted in our invention of a novel resonator structure based on a combination of interdigital transducer (IDT) and piezoelectric layer, XBAR ® , which exhibits performance parameters suitable for 5G, 5-7GHz WiFi and Ultra Wideband applications - high frequency operation, large bandwidth and high power reliability. Using ISN ® we have developed an IP portfolio of more than 320 patents filed or issued, with more than 165 filed or issued targeting XBAR ® , 5G and high frequency WiFi applications. In addition, with continued requirements for increasing numbers of filter designs our innovative software platform addresses the need for increased designer efficiency, reduced time to market and lower unit costs in the designs of filters for radio frequency, or RF Front-Ends for the mobile device, Customer Premise Equipment (CPE) and Infrastructure industries. The RF Front-End, or RFFE, is the circuitry responsible for analog signal processing and is located between the device’s antenna and its digital circuitry. Filters are a critical component of the RFFE used to select desired radio frequency signals and reject unwanted signals. We believe licensing our designs is the most direct and effective means of validating our IP and IP related libraries and demonstrating the power and accuracy of our ISN ® multi-physics EDA platform. Our target customers make part, or all of, the RFFE. We intend to retain ownership of our IP, trade secrets and designs, and we expect to be compensated through license fees and royalties either prepaid at contract inception or based on sales of RFFE filters that incorporate our IP, trade secrets and designs. Capital Resources and Liquidity As of March 31, 2021, our accumulated deficit totaled $159.7 million. In the three months ended March 31, 2021 our net loss totaled $8.8 million and we used $7.8 million of cash for operating activities, the purchase of property and equipment and expenditures for patents. To date we have not generated significant revenues to enable profitability. We expect to continue to incur significant losses. These factors raise substantial doubt regarding our ability to continue as a going concern. At March 31, 2021 we had cash and cash equivalents of $21.6 million. Subsequent to March 31, 2021, but prior to the publication of the financial statements on this Form 10-Q, we raised $0.5 million of cash from sales of common stock using our At-The-Market Equity Offering Sales Agreement. In the absence of a significant revenue increase these cash resources will provide sufficient funding into the first quarter of 2022. We are subject to the risks and uncertainties associated with a new business. We also have been impacted by the COVID-19 pandemic which has added additional risks and uncertainties. Our continuance as a going concern is dependent on our future profitability. We are actively pursuing expanding our technology portfolio, increasing our revenue opportunities by completing deliverables under current customer contracts and entering into new customer contracts, and efficiently managing operations and exploring cost saving opportunities. We may not be successful in these efforts. We may need to seek to raise additional capital from the sale of equity securities or incurrence of indebtedness. There can be no assurance that additional financing will be available to us on acceptable terms, or at all in which case we might be forced to make substantial reductions in our operating expenses which could adversely affect our ability to implement our business plan and ultimately our viability as a company. Even if available, such capital may be dilutive to existing stockholders. The accompanying condensed consolidated financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates —The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes included in our Annual Report for the year ended December 31, 2020 filed with the SEC on March 12, 2021. The year-end condensed balance sheet was derived from our audited consolidated financial statements. Our unaudited interim condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance; (b) the useful lives for depreciable and amortizable assets and (c) the estimated efforts to be expended, as well as our ability to achieve milestones, in connection with our revenue contracts. On an ongoing basis, we evaluate our estimates and judgments compared to historical experience and expected trends. Additionally, the global economic effects resulting from the COVID-19 pandemic may cause changes to estimates that would have a material impact on our financial statements, particularly with respect to timing of revenue recognition due to delays in meeting our performance obligations and collectability of our accounts receivable. As of the date of issuance of these financial statements, our results have not been significantly impacted by the COVID-19 pandemic; however, we continue to monitor the situation. Consolidation —The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated. Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. Restricted Cash —Restricted cash consists of a pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our offices in Goleta, California. The letter of credit was reissued in November 2020 due to a change in the property owner. No changes were made to the terms of the letter of credit. The balance as of March 31, 2021 and December 31, 2020 was $105,000. The terms of the letter of credit allow for a step-down of $50,000 annually upon performance of certain events, primarily no late or defaulted payments. See also Note 7- Leases, for further details. Fair Value of Financial Instruments —We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Accounts Receivable —Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact ability to collect the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. There was no allowance for doubtful accounts at March 31, 2021 or December 31, 2020. Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from two Intangibles, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At March 31, 2021 and December 31, 2020, intangible assets, net includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. We capitalize certain patent filing costs up to the point of issuance and then amortize the costs over the life of the patent. Costs associated with maintenance or renewal of existing patents are expensed as incurred. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or be abandoned as they no longer have a probable economic value. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses. Goodwill— Goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. Revenue Recognition —Revenue is recognized upon the transfer of control of promised goods or services to the customers, generally over time, in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of the recognized portion of upfront, non-refundable, prepaid royalties received in connection with filter design projects with customers. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In most cases, upfront non-refundable payments related to design development are recognized over a period of 12 months to 18 months as that is the amount of time it generally takes to develop a design; however, the actual amount of time depends on the complexity of the filter being designed. Contracts generally include non-refundable fees, or prepaid royalties, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Some contracts also include royalties that are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. Payment is generally due within 30 days. We apply the exemptions available in ASC Topic 606, Revenue from Contracts with Customers , or ASC 606, to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty. Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We determine if an arrangement is a lease at lease inception. Operating leases are included in right-of-use (“ROU”) lease assets, other current liabilities (current portion of lease obligations), and long term lease obligations on our balance sheets. ROU lease assets represent our right to use an underlying asset for the lease term and lease obligations represent our obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. We evaluate renewal options at lease inception and on an ongoing basis and include renewal options which we are reasonably certain to exercise in our expected lease term when classifying leases and measuring lease liabilities. We allocate the consideration between lease and nonlease components and exclude nonlease components from our recognized lease assets and liabilities. Minimum lease payments, including scheduled rent increases, are recognized as lease expenses on a straight-line basis over the applicable lease term. We recognize lease expenses within research and development and sales, marketing and administration expenses on a straight-line basis over the lease term. We are not party to any leases for which we are the lessor. Finance Lease —The finance lease asset represents our right to use an underlying asset for the lease term and the finance lease liability represents the present value of lease payments not yet paid. Interest expense on the finance lease is recorded over the lease term and is presented in interest expense, based on the effective interest method. The right of use asset is amortized over the term of the related lease. Stock-Based Compensation —We account for stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . We use the Black-Scholes option valuation model for estimating fair value at the date of grant. We account for restricted stock units issued at fair value, based on the market price of our stock on the date of grant. Compensation expense is recognized over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. We recognize compensation expense for restricted stock units with market conditions using a graded vesting model, based on the probability of the market condition being met. In the case of award modifications, we account for the modification in accordance with ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options, the exercise of warrants and the vesting of restricted stock unit awards. Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the condensed consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the condensed consolidated statements of comprehensive loss. Recent Accounting Pronouncements Credit Losses— In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments- Credit Losses (Topic 326). In April and November 2019, and February 2020, the FASB issued implementation amendments to the June 2016 ASU (collectively, the amended guidance). The amended guidance replaced the current incurred loss methodology for credit losses with a current expected credit loss ("CECL") model, which requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The amended guidance expanded the information that an entity must consider in developing its expected credit loss estimates. Additionally, the updates amended the accounting for credit losses for purchased financial assets with a more-than-significant amount of credit deterioration since origination. The amended guidance requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimated credit losses. Early |
REVENUE RECOGNITION
REVENUE RECOGNITION | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE RECOGNITION | REVENUE RECOGNITION We record contract assets and contract liabilities in connection with revenue recognized for filter design projects. Contract Assets - Contract assets, other than accounts receivable, consist of unbilled revenue and generally arise when revenue is recognized ahead of invoicing the customer. Contract asset balances, if any, are included in prepaid expenses and other current assets in our condensed consolidated balance sheets. We had no contract assets during the three months ended March 31, 2021 and 2020. Contract Liabilities - Our contract liabilities consist of deferred revenue, which represents the revenue associated with remaining performance obligations within our customer contracts. We classify contract liabilities as current or long-term based on the expected timing of the remaining performance obligations. Generally, our contract liabilities are expected to be recognized in one year or less. Customer deposits and deferred revenue are separately stated in our condensed consolidated balance sheets. Summary of changes in contract liabilities for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Contract liabilities Contract liabilities, beginning $ 1,783 $ 1,731 Recognition of revenue included in beginning of year contract liabilities $ (592) $ (537) Contract liabilities, net of revenue recognized on contracts during the period $ 104 $ 275 Contract liabilities, ending $ 1,295 $ 1,469 We derive a substantial majority of our revenue from a single customer. Effective September 30, 2019 we entered into a collaboration and license agreement with Murata Manufacturing Co., Ltd. Pursuant to the collaboration agreement, we have agreed with Murata to collaborate on the development of proprietary circuit designs using our XBAR® technology, and we licensed to Murata rights for products in four specific radio frequencies, or bands. Murata has agreed to pay us up to an aggregate of $9.0 million of total consideration in the form of pre-paid royalties for the licensed designs and certain other intellectual property developed in the collaboration, payable in installments over a multi-year development period, with each installment conditional upon our achievement of certain milestones and deliverables acceptable to Murata in its discretion. Murata may terminate the collaboration agreement at any time upon thirty (30) days prior written notice to us. Murata’s rights to our XBAR® technology are exclusive for a period of 30 months, through March 2022, during which period we may not grant to any third party the right to develop, make, have made, use, sell, offer for sale or import any filter or resonator produced through the use of the XBAR® technology for use in mobile communication devices. Under the collaboration agreement, the first payment of $2.0 million was a non-refundable upfront payment received in October 2019 and the second payment of $2.5 million was collected in September 2020 upon the achievement of the second milestone. In accordance with the guidance of ASC 606, we are required to evaluate the variable consideration within the contract, primarily the milestone payments, and assess the likelihood of achievement in determining our transaction price. Additionally, we must assess whether the variable consideration is constrained and whether recording such variable revenue may result in a significant reversal of revenue due to uncertainties. We continue to evaluate variable consideration for inclusion in the transaction price, and ultimately the revenue recognized, at each reporting period. We recognize revenue for the Murata contract over the estimated design development period, based on the level of effort expended over total expected costs, as the services are performed. For the periods ended March 31, 2021 and 2020, we have determined that some of the milestone payments due upon achievement of certain performance criteria are constrained and are thus not included in the transaction price. Therefore, revenue related to those milestone payments has not been recognized. Revenue recognition related to each |
WARRANTS
WARRANTS | 3 Months Ended |
Mar. 31, 2021 | |
Warrants and Rights Note Disclosure [Abstract] | |
WARRANTS | WARRANTS From time to time, we have issued warrants to purchase shares of common stock. These warrants were issued in connection with financing transactions or in exchange for consulting services. Our warrants were subject to standard anti-dilution provisions applicable to shares of our common stock. All of the warrants issued have been either exercised, cancelled, or expired as of December 31, 2020. A roll-forward of warrant share activity from January 1, 2020 to March 31, 2020 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Outstanding Warrants as of March 31, 2020 Consulting Warrants $0.01 6/17/2020 6,667 — 6,667 Financing Warrants $3.35 6/17/2020 62,530 — 62,530 Private Placement Warrants - September 2017 $4.85 9/28/2020 1,966,319 — 1,966,319 Placement Agent Warrants $4.85 9/28/2020 98,846 — 98,846 2,134,362 — 2,134,362 |
STOCKHOLDERS' EQUITY AND LOSS P
STOCKHOLDERS' EQUITY AND LOSS PER SHARE | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
STOCKHOLDERS' EQUITY AND LOSS PER SHARE | STOCKHOLDERS’ EQUITY AND LOSS PER SHARE Common Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 100,000,000 shares of common stock. Holders of our common stock are entitled to dividends as and when declared by the Board of Directors, subject to rights and holders of all classes of stock outstanding having priority rights to dividends. There have been no dividends declared to date. Each share of common stock is entitled to one vote. On February 6, 2020, we entered into an underwriting agreement relating to an underwritten public offering of 16,666,667 shares of the Company’s common stock, $0.001 par value, at an offering price to the public of $1.50 per share. Pursuant to the underwriting agreement, the Company granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock on the same terms and conditions. The underwriters exercised their option with respect to all 2,500,000 additional shares on February 10, 2020. We consummated the sale of an aggregate of 19,166,667 shares of our common stock, including the 2,500,000 shares subject to the underwriters’ over-allotment option, on February 11, 2020. We received gross proceeds of approximately $28.8 million, including $201,000 for 134,000 shares purchased by Park City Capital, a significant shareholder. Net proceeds were approximately $26.4 million after deducting the underwriting discount and expenses paid by us. Under a Form S-3 universal shelf registration statement filed in November 2018, on August 14, 2020, we entered into an At-The-Market Equity Offering Sales Agreement whereby we may offer and sell from time to time, shares of our common stock, par value $0.001 per share, up to an aggregate offering price of $25.0 million (the "ATM equity program"). As of December 31, 2020, we sold an aggregate of 4,609,701 shares of common stock under the ATM equity program, at an average price of $2.48 per share, for gross proceeds of $11.4 million and net proceeds of $11.0 million, after deducting commissions and other offering expenses. During the three months ended March 31, 2021, we sold an aggregate of 773,900 shares of common stock under the ATM equity program, at an average price of $5.45 per share, for gross proceeds of $4.2 million and net proceeds of $4.1 million, after deducting commissions and other offering expenses. As of March 31, 2021, we had $9.4 million of common stock remaining to be sold under this Form S-3 and ATM equity program. We have filed a Form S-3 universal shelf registration statement with the SEC, which has not become effective. After it becomes effective, the universal shelf registration statement on Form S-3 will permit us to sell, in one or more public offerings, shares of our common stock, shares of preferred stock or debt securities, or any combination of such securities and warrants to purchase securities, for proceeds in an aggregate amount of up to $100.0 million. Preferred Stock Pursuant to our amended and restated certificate of incorporation, we are authorized to issue 3,000,000 shares of preferred stock. The Board of Directors has the authority, without action by our stockholders, to designate and issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. To-date, no preferred shares have been issued. Loss Per Share The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Three Months Ended March 31, 2021 2020 Common stock warrants — 2,134,362 Common stock options 1,036,358 1,216,765 Non-vested restricted stock unit awards 4,263,345 3,761,964 Total shares excluded from net loss per share attributable to common stockholders 5,299,703 7,113,091 |
STOCK-BASED COMPENSATION
STOCK-BASED COMPENSATION | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
STOCK-BASED COMPENSATION | STOCK-BASED COMPENSATION 2014 Omnibus Incentive Plan In January 2014, our board of directors approved the 2014 Omnibus Incentive Plan and amended and restated the plan in March 2014. Our stockholders approved the Amended and Restated 2014 Omnibus Incentive Plan, or the 2014 Plan, in March 2014. Our 2014 Plan initially permitted for the issuance of equity-based instruments covering up to a total of 1,400,000 shares of common stock. Our board of directors and stockholders approved an increase of 1,300,000 shares in June 2016, an increase of 3,250,000 shares in June 2017, an increase of 4,000,000 shares in June 2019, and an increase of 5,000,000 shares in June 2020, bringing the total shares allowed under the plan to 14,950,000. As of March 31, 2021 there were 4,311,407 shares available to issue under the 2014 Plan. The table below represents stock option award activity for the three months ended March 31, 2021: Outstanding Exercisable January 1, 2021 1,140,975 955,302 Granted/Vested 5,000 20,817 Exercised (104,465) (104,465) Cancelled or expired (5,152) — March 31, 2021 1,036,358 871,654 The weighted-average exercise price as of March 31, 2021 for stock options outstanding and stock options exercisable was $4.64 and $4.94, respectively. The table below represents restricted stock activity for the three months ended March 31, 2021: Number of Restricted Share Units Outstanding at January 1, 2021 3,038,785 Granted 1,434,007 Vested (195,000) Forfeited (14,447) Outstanding at March 31, 2021 4,263,345 Total stock-based compensation recorded in the condensed consolidated statements of comprehensive loss is allocated as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 972 $ 648 Sales, marketing and administration $ 1,175 $ 731 Total stock-based compensation $ 2,147 $ 1,379 |
LEASES
LEASES | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
LEASES | LEASES We lease facilities under two non-cancelable operating leases. The leases expire between January 2022 and November 2024 and include renewal provisions for two On May 1, 2020 we entered into an amendment for one of our non-cancelable facilities operating leases, under which certain rent payments were deferred and the term of the lease was extended by three months to November 30, 2024. The base rent was deferred for three months and the deferred amount will be repaid over the remaining balance of the modified lease term. In addition, operating expenses were deferred for three months with the deferred amount due upon the annual true-up of operating expenses, which occurred in April 2021. As a result of the lease amendment, we recorded additional ROU assets, and related lease liabilities, of $115,000. One facility lease requires us to maintain a cash security deposit of $50,000 and also a $105,000 letter of credit in favor of the lessor. The letter of credit was originally for $200,000 at lease inception and steps down $50,000 at each anniversary date if there have been no monetary defaults. The letter of credit is secured by a pledge in favor of the issuing bank of a $105,000 mutual fund account which is classified as restricted cash in our balance sheet. Lease renewal options are at our discretion. No renewal options have been recognized in our right-of-use assets and lease liabilities as of March 31, 2021. Our lease agreements do not require material variable minimum lease payments, residual value guarantees or restrictive covenants. In December 2020, we entered into a lease for lab equipment. The lease is for 60 months and bears an interest rate of 5.99%. After evaluation of the lease under ASU No. 2016-02, Leases (Topic 842) , we determined the lease to be a finance lease. We recorded a right-of-use asset and lease liability of $204,000 upon inception of the lease. The Company's weighted average remaining lease term and weighted average discount rate as of March 31, 2021 is shown below: Weighted average remaining term (years) Operating leases 3.42 Finance lease 4.67 Weighted average discount rate (%) Operating leases 4.75 % Finance lease 5.99 % Minimum future maturities of lease liabilities recognized on the condensed consolidated balances sheets as of March 31, 2021 (in thousands): Operating Leases Finance Lease April 1, 2021 - December 31, 2021 $ 584 $ 38 2022 586 50 2023 584 50 2024 544 50 2025 — 46 Total minimum lease payments $ 2,298 $ 234 Less: imputed interest (175) (30) Total operating lease liabilities $ 2,123 $ 204 Operating lease costs were $286,000 for the three months ended March 31, 2021, of which $193,000 and $93,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Operating lease costs were $283,000 for the three months ended March 31, 2020, of which $209,000 and $74,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Cash paid for amounts included in the measurement of operating lease liabilities were $192,000 and $180,000 for the three months ended March 31, 2021 and 2020, respectively, which is included in operating activities in the condensed consolidated statements of cash flows. Finance lease amortization for the three months ended March 31, 2021 and 2020 was $10,000 and zero, respectively, and is included in research and development expenses. |
LEASES | LEASES We lease facilities under two non-cancelable operating leases. The leases expire between January 2022 and November 2024 and include renewal provisions for two On May 1, 2020 we entered into an amendment for one of our non-cancelable facilities operating leases, under which certain rent payments were deferred and the term of the lease was extended by three months to November 30, 2024. The base rent was deferred for three months and the deferred amount will be repaid over the remaining balance of the modified lease term. In addition, operating expenses were deferred for three months with the deferred amount due upon the annual true-up of operating expenses, which occurred in April 2021. As a result of the lease amendment, we recorded additional ROU assets, and related lease liabilities, of $115,000. One facility lease requires us to maintain a cash security deposit of $50,000 and also a $105,000 letter of credit in favor of the lessor. The letter of credit was originally for $200,000 at lease inception and steps down $50,000 at each anniversary date if there have been no monetary defaults. The letter of credit is secured by a pledge in favor of the issuing bank of a $105,000 mutual fund account which is classified as restricted cash in our balance sheet. Lease renewal options are at our discretion. No renewal options have been recognized in our right-of-use assets and lease liabilities as of March 31, 2021. Our lease agreements do not require material variable minimum lease payments, residual value guarantees or restrictive covenants. In December 2020, we entered into a lease for lab equipment. The lease is for 60 months and bears an interest rate of 5.99%. After evaluation of the lease under ASU No. 2016-02, Leases (Topic 842) , we determined the lease to be a finance lease. We recorded a right-of-use asset and lease liability of $204,000 upon inception of the lease. The Company's weighted average remaining lease term and weighted average discount rate as of March 31, 2021 is shown below: Weighted average remaining term (years) Operating leases 3.42 Finance lease 4.67 Weighted average discount rate (%) Operating leases 4.75 % Finance lease 5.99 % Minimum future maturities of lease liabilities recognized on the condensed consolidated balances sheets as of March 31, 2021 (in thousands): Operating Leases Finance Lease April 1, 2021 - December 31, 2021 $ 584 $ 38 2022 586 50 2023 584 50 2024 544 50 2025 — 46 Total minimum lease payments $ 2,298 $ 234 Less: imputed interest (175) (30) Total operating lease liabilities $ 2,123 $ 204 Operating lease costs were $286,000 for the three months ended March 31, 2021, of which $193,000 and $93,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Operating lease costs were $283,000 for the three months ended March 31, 2020, of which $209,000 and $74,000 are included in research and development expenses and sales, marketing and administration expenses, respectively. Cash paid for amounts included in the measurement of operating lease liabilities were $192,000 and $180,000 for the three months ended March 31, 2021 and 2020, respectively, which is included in operating activities in the condensed consolidated statements of cash flows. Finance lease amortization for the three months ended March 31, 2021 and 2020 was $10,000 and zero, respectively, and is included in research and development expenses. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2021 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | RELATED PARTY TRANSACTIONS In August 2019, we entered into a consulting agreement with a member of our board of directors. Under the agreement, the board member would provide technical advisory services for cash payments totaling $50,000 paid in twelve equal monthly installments as well as an award of restricted stock units equal in value to $100,000 as of the grant date. In the event the board member continues to perform services in subsequent years, the Company will issue new grants equal to no less than $100,000 worth of restricted stock units in January of each additional year with such grants vesting at the end of each year so long as the services are still being provided. The agreement is cancelable at any time by either the Company or the board member. Services have continued to be provided since inception of the agreement. During the three months ended March 31, 2021, we recorded expenses of $36,500, in connection with the consulting agreement, of which $12,500 is included in general and administrative expenses and $24,000 is included in research and development expenses. During the three months ended March 31, 2020, we recorded expenses of $36,500, in connection with the consulting agreement, of which $12,500 is included in general and administrative expenses and $24,000 is included in research and development expenses. As of March 31, 2021, there was $4,000 due to the board member under this consulting agreement. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Legal Proceedings — W e are not party to any legal proceedings. We may, from time to time, be party to litigation and subject to claims incident to the ordinary course of business. As our growth continues, we may become party to an increasing number of litigation matters and claims. The outcome of litigation and claims cannot be predicted with certainty, and the resolution of any future matters could materially affect our future financial position, results of operations or cash flows. Legal fees and other costs associated with legal proceedings are expensed as incurred. We assess, in conjunction with our legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. We evaluate developments in legal proceedings and other matters on a quarterly basis. As of March 31, 2021 and 2020, there was no litigation or contingency with at least a reasonable possibility of a material loss. No losses have been recorded during the three months ended March 31, 2021 and 2020, respectively, with respect to litigation or loss contingencies. Intellectual Property Indemnities —We indemnify certain customers and manufacturers against liability arising from third-party claims of intellectual property rights infringement related to our products. These indemnities may appear in license agreements, development agreements and manufacturing agreements, may not be limited in amount or duration and generally survive the expiration date of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, we are unable to determine the maximum amount of losses that we could incur related to such indemnifications. Director and Officer Indemnities and Contractual Guarantees —We have entered into indemnification agreements with our directors and executive officers, which require us to indemnify such individuals to the fullest extent permitted by Delaware law. Our indemnification obligations under such agreements are not limited in amount or duration. Certain costs incurred in connection with such indemnifications may be recovered under certain circumstances under various insurance policies. Given that the amount of any potential liabilities related to such indemnities cannot be determined until a lawsuit has been filed, we are unable to determine the maximum amount of losses that we could incur relating to such indemnities. We have also entered into severance and change in control agreements with certain of our executives. These agreements provide for the payment of specific compensation benefits to such executives upon the termination of their employment with us. Guarantees and Indemnities —In the normal course of business, we are occasionally required to undertake indemnification for which we may be required to make future payments under specific circumstances. We review our exposure under such obligations no less than annually, or more frequently as required. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. Historically, any such amounts that become payable have not had a material negative effect on our business, financial condition or results of operations. We maintain general and product liability insurance which may provide a source of recovery to us in the event of an indemnification claim. |
SEGMENTS AND GEOGRAPHIC INFORMA
SEGMENTS AND GEOGRAPHIC INFORMATION | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
SEGMENTS AND GEOGRAPHIC INFORMATION | SEGMENTS AND GEOGRAPHIC INFORMATION We operate in a single segment to design radio frequency filters. In making operating decisions, the Chief Operating Decision Maker, our Chief Executive Officer, primarily considers consolidated financial performance and allocates resources accordingly. The table below presents our revenue by geographic area (in thousands) and is categorized based on the location of the customer. Three Months Ended March 31, 2021 2020 Japan $ 494 $ 501 China 93 36 Other 21 7 Total revenue $ 608 $ 544 |
SUMMARY OF SIGNIFICANT ACCOUN_2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Use of Estimates | Basis of Presentation and Use of Estimates—The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the related notes included in our Annual Report for the year ended December 31, 2020 filed with the SEC on March 12, 2021. The year-end condensed balance sheet was derived from our audited consolidated financial statements. Our unaudited interim condensed consolidated financial statements include, in the opinion of management, all adjustments, consisting of normal and recurring items, necessary for the fair statement of the condensed consolidated financial statements. The operating results for the three months ended March 31, 2021 are not necessarily indicative of the results expected for the full year ending December 31, 2021. Significant estimates made in preparing these financial statements include (a) assumptions to calculate the fair values of financial instruments, warrants and equity instruments and other liabilities and the deferred tax asset valuation allowance; (b) the useful lives for depreciable and amortizable assets and (c) the estimated efforts to be expended, as well as our ability to achieve milestones, in connection with our revenue contracts. On an ongoing basis, we evaluate our estimates and judgments compared to historical experience and expected trends. Additionally, the global economic effects resulting from the COVID-19 pandemic may cause changes to estimates that would have a material impact on our financial statements, particularly with respect to timing of revenue recognition due to delays in meeting our performance obligations and collectability of our accounts receivable. As of the date of issuance of these financial statements, our results have not been significantly impacted by the COVID-19 pandemic; however, we continue to monitor the situation |
Consolidation | Consolidation —The accompanying financial statements include the accounts of the Company and its wholly-owned subsidiary, GVR Trade, S.A. All significant intercompany balances and transactions have been eliminated. |
Cash and Cash Equivalents | Cash and Cash Equivalents —We consider all liquid instruments purchased with a maturity of three months or less to be cash equivalents. |
Concentration of Credit Risk | Concentration of Credit Risk —We maintain bank accounts at one U.S. financial institution. The U.S. bank accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per account owner. GVR Trade S.A., our wholly owned Swiss-based subsidiary maintains checking accounts at one major national financial institution. Additionally, we maintain a checking account with a very minimal balance at one bank in South Korea, which is used to fund payroll and rent in South Korea. Management believes we are not exposed to significant credit risk due to the financial position of the depository institutions in which our deposits are held. |
Restricted Cash | Restricted Cash—Restricted cash consists of a pledged mutual fund account which is held as collateral against a letter of credit issued in May 2018 in connection with the lease of our offices in Goleta, California. The letter of credit was reissued in November 2020 due to a change in the property owner. No changes were made to the terms of the letter of credit. The balance as of March 31, 2021 and December 31, 2020 was $105,000. The terms of the letter of credit allow for a step-down of $50,000 annually upon performance of certain events, primarily no late or defaulted payments. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments—We measure certain financial assets and liabilities at fair value based on the exit price notion, or price that would be received for an asset or paid to transfer a liability, in an orderly transaction between the market participants at the measurement date. The carrying amounts of our financial instruments, including cash equivalents, restricted cash, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. |
Accounts Receivable | Accounts Receivable—Trade accounts receivable are stated net of allowances for doubtful accounts. Management estimates the allowance for doubtful accounts based on review and analysis of specific customer balances that may not be collectible, customer payment history and any other customer-specific information that may impact ability to collect the receivable. Accounts are considered for write-off when they become past due and when it is determined that the probability of collection is remote. |
Property and Equipment | Property and Equipment —Property and equipment consists of leasehold improvements associated with our corporate offices, software purchased during the normal course of business, equipment and office furniture and fixtures, all of which are recorded at cost. Depreciation and amortization is recorded using the straight-line method over the respective useful lives of the assets ranging from two |
Intangible Assets, net | Intangibles, net —Intangible assets are recorded at cost and amortized over the useful life. In the case of business combinations, intangible assets are recorded at fair value. At March 31, 2021 and December 31, 2020, intangible assets, net includes patents and a domain name and other intangible assets purchased as part of our acquisition of GVR, including customer relationships, technology and a trademark. We capitalize certain patent filing costs up to the point of issuance and then amortize the costs over the life of the patent. Costs associated with maintenance or renewal of existing patents are expensed as incurred. Intangible assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In certain cases, patents may expire or be abandoned as they no longer have a probable economic value. In such cases we write off the capitalized patent costs as patent abandonment costs which are included in research and development expenses. |
Goodwill | Goodwill—Goodwill represents the difference between the price paid to acquire GVR and the fair value of the assets acquired, net of assumed liabilities. We review goodwill for impairment annually and whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. |
Revenue Recognition | Revenue Recognition —Revenue is recognized upon the transfer of control of promised goods or services to the customers, generally over time, in an amount that reflects the consideration we expect to receive in exchange for those products or services. Revenue consists primarily of the recognized portion of upfront, non-refundable, prepaid royalties received in connection with filter design projects with customers. Our performance obligation is to design a licensable filter in accordance with customer specifications. The license of the completed design is considered part of this performance obligation as the design and licensing of the filter are highly interdependent. We recognize revenue from our design services based on efforts expended to date. At the end of each reporting period, we reassess our measure of progress and adjust revenue when appropriate. We record the expenses related to these projects in the periods incurred and they are generally included in research and development expense. In most cases, upfront non-refundable payments related to design development are recognized over a period of 12 months to 18 months as that is the amount of time it generally takes to develop a design; however, the actual amount of time depends on the complexity of the filter being designed. Contracts generally include non-refundable fees, or prepaid royalties, and may include milestone payments based upon the successful completion of certain deliverables. Milestone payments represent variable consideration, and we use the "most likely amount" approach to determine the amount we ultimately expect to receive. Upon completion of design services, our customers retain a license over the completed design. The license will typically last for a minimum of two years, and in many cases for the life of the design. Some contracts also include royalties that are sales-based, and we recognize royalty revenue upon shipment, by our customer, of products that include our licensed design. Payment is generally due within 30 days. We apply the exemptions available in ASC Topic 606, Revenue from Contracts with Customers , or ASC 606, to not disclose information about 1) remaining performance obligations that have original expected durations of one year or less and 2) variable consideration that is a sales-based or usage-based royalty. |
Research and Development | Research and Development —Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with ASC Topic 730-10, Research and Development . |
Operating and Finance Leases | Operating Leases —We lease office space and research facilities under operating leases. Certain lease agreements contain free or escalating rent payment provisions. We determine if an arrangement is a lease at lease inception. Operating leases are included in right-of-use (“ROU”) lease assets, other current liabilities (current portion of lease obligations), and long term lease obligations on our balance sheets. ROU lease assets represent our right to use an underlying asset for the lease term and lease obligations represent our obligation to make lease payments arising from the lease. Operating ROU lease assets and obligations are recognized at the commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The ROU lease asset also includes any lease payments made and excludes lease incentives. We evaluate renewal options at lease inception and on an ongoing basis and include renewal options which we are reasonably certain to exercise in our expected lease term when classifying leases and measuring lease liabilities. We allocate the consideration between lease and nonlease components and exclude nonlease components from our recognized lease assets and liabilities. Minimum lease payments, including scheduled rent increases, are recognized as lease expenses on a straight-line basis over the applicable lease term. We recognize lease expenses within research and development and sales, marketing and administration expenses on a straight-line basis over the lease term. We are not party to any leases for which we are the lessor. Finance Lease —The finance lease asset represents our right to use an underlying asset for the lease term and the finance lease liability represents the present value of lease payments not yet paid. Interest expense on the finance lease is recorded over the lease term and is presented in interest expense, based on the effective interest method. The right of use asset is amortized over the term of the related lease. |
Stock-Based Compensation | Stock-Based Compensation —We account for stock options in accordance with ASC Topic 718, Compensation-Stock Compensation . We use the Black-Scholes option valuation model for estimating fair value at the date of grant. We account for restricted stock units issued at fair value, based on the market price of our stock on the date of grant. Compensation expense is recognized over the period during which the recipient renders the required services to the Company generally using the straight-line single option method. We recognize compensation expense for restricted stock units with market conditions using a graded vesting model, based on the probability of the market condition being met. In the case of award modifications, we account for the modification in accordance with ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting , whereby we recognize the effect of the modification in the period the award is modified. Stock-based compensation expense is included in research and development expenses and general and administrative expenses. |
Earnings Per Share, or EPS | Earnings Per Share, or EPS —EPS is computed in accordance with ASC Topic 260, Earnings per Share , and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options, the exercise of warrants and the vesting of restricted stock unit awards. |
Income Taxes | Income Taxes —We account for income taxes in accordance with ASC Topic 740, Income Taxes , or ASC 740, which requires the recognition of deferred tax assets and liabilities for the future consequences of events that have been recognized in our condensed consolidated financial statements or tax returns. The measurement of the deferred items is based on enacted tax laws. In the event the future consequences of differences between financial reporting bases and the tax bases of our assets and liabilities result in a deferred tax asset, ASC 740 requires an evaluation of the probability of being able to realize the future benefits indicated by such asset. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion or the entire deferred tax asset will not be realized. As part of the process of preparing our consolidated financial statements, we are required to estimate our income tax expense in each of the jurisdictions in which we operate. We also assess temporary differences resulting from differing treatment of items for tax and accounting differences. We record a valuation allowance to reduce the deferred tax assets to the amount of future tax benefit that is more likely than not to be realized. |
Foreign Currency Remeasurement | Foreign Currency Translation —The Swiss Franc has been determined to be the functional currency for the net assets of our Swiss-based subsidiary. We translate the assets and liabilities to U.S. dollars at each reporting period using exchange rates in effect at the balance sheet date and record the effects of the foreign currency translation in accumulated other comprehensive loss in shareholders' equity. We translate the income and expenses to U.S. dollars at each reporting period using the average exchange rate in effect for the period and record the effects of the foreign currency translation as other comprehensive income (loss) in the condensed consolidated statements of comprehensive loss. Gains and losses resulting from foreign currency transactions are included in net loss in the condensed consolidated statements of comprehensive loss. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Credit Losses— In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments- Credit Losses (Topic 326). In April and November 2019, and February 2020, the FASB issued implementation amendments to the June 2016 ASU (collectively, the amended guidance). The amended guidance replaced the current incurred loss methodology for credit losses with a current expected credit loss ("CECL") model, which requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The amended guidance expanded the information that an entity must consider in developing its expected credit loss estimates. Additionally, the updates amended the accounting for credit losses for purchased financial assets with a more-than-significant amount of credit deterioration since origination. The amended guidance requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimated credit losses. Early |
REVENUE RECOGNITION (Tables)
REVENUE RECOGNITION (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Changes in Contract Asset and Liability Balances | Summary of changes in contract liabilities for the three months ended March 31, 2021 and 2020 (in thousands): Three Months Ended March 31, 2021 2020 Contract liabilities Contract liabilities, beginning $ 1,783 $ 1,731 Recognition of revenue included in beginning of year contract liabilities $ (592) $ (537) Contract liabilities, net of revenue recognized on contracts during the period $ 104 $ 275 Contract liabilities, ending $ 1,295 $ 1,469 |
WARRANTS (Tables)
WARRANTS (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Warrants and Rights Note Disclosure [Abstract] | |
Schedule of Warrant Activity | A roll-forward of warrant share activity from January 1, 2020 to March 31, 2020 is shown in the following table: Exercise Price Expiration Date Issued and Warrants Issued and Outstanding Warrants as of March 31, 2020 Consulting Warrants $0.01 6/17/2020 6,667 — 6,667 Financing Warrants $3.35 6/17/2020 62,530 — 62,530 Private Placement Warrants - September 2017 $4.85 9/28/2020 1,966,319 — 1,966,319 Placement Agent Warrants $4.85 9/28/2020 98,846 — 98,846 2,134,362 — 2,134,362 |
STOCKHOLDERS' EQUITY AND LOSS_2
STOCKHOLDERS' EQUITY AND LOSS PER SHARE (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Equity [Abstract] | |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following table presents the number of shares excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods below: Three Months Ended March 31, 2021 2020 Common stock warrants — 2,134,362 Common stock options 1,036,358 1,216,765 Non-vested restricted stock unit awards 4,263,345 3,761,964 Total shares excluded from net loss per share attributable to common stockholders 5,299,703 7,113,091 |
STOCK-BASED COMPENSATION (Table
STOCK-BASED COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement [Abstract] | |
Summary of Stock Option Activity | The table below represents stock option award activity for the three months ended March 31, 2021: Outstanding Exercisable January 1, 2021 1,140,975 955,302 Granted/Vested 5,000 20,817 Exercised (104,465) (104,465) Cancelled or expired (5,152) — March 31, 2021 1,036,358 871,654 |
Schedule of Share-based Compensation, Restricted Stock Activity | The table below represents restricted stock activity for the three months ended March 31, 2021: Number of Restricted Share Units Outstanding at January 1, 2021 3,038,785 Granted 1,434,007 Vested (195,000) Forfeited (14,447) Outstanding at March 31, 2021 4,263,345 |
Schedule of Stock-based Compensation | Total stock-based compensation recorded in the condensed consolidated statements of comprehensive loss is allocated as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 972 $ 648 Sales, marketing and administration $ 1,175 $ 731 Total stock-based compensation $ 2,147 $ 1,379 |
LEASES (Tables)
LEASES (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Leases [Abstract] | |
Lessee, Operating Lease, Lease Terms | The Company's weighted average remaining lease term and weighted average discount rate as of March 31, 2021 is shown below: Weighted average remaining term (years) Operating leases 3.42 Finance lease 4.67 Weighted average discount rate (%) Operating leases 4.75 % Finance lease 5.99 % |
Operating Lease Maturity | Minimum future maturities of lease liabilities recognized on the condensed consolidated balances sheets as of March 31, 2021 (in thousands): Operating Leases Finance Lease April 1, 2021 - December 31, 2021 $ 584 $ 38 2022 586 50 2023 584 50 2024 544 50 2025 — 46 Total minimum lease payments $ 2,298 $ 234 Less: imputed interest (175) (30) Total operating lease liabilities $ 2,123 $ 204 |
Finance Leases Maturity | Minimum future maturities of lease liabilities recognized on the condensed consolidated balances sheets as of March 31, 2021 (in thousands): Operating Leases Finance Lease April 1, 2021 - December 31, 2021 $ 584 $ 38 2022 586 50 2023 584 50 2024 544 50 2025 — 46 Total minimum lease payments $ 2,298 $ 234 Less: imputed interest (175) (30) Total operating lease liabilities $ 2,123 $ 204 |
SEGMENTS AND GEOGRAPHIC INFOR_2
SEGMENTS AND GEOGRAPHIC INFORMATION (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Revenue from External Customers by Geographic Areas | The table below presents our revenue by geographic area (in thousands) and is categorized based on the location of the customer. Three Months Ended March 31, 2021 2020 Japan $ 494 $ 501 China 93 36 Other 21 7 Total revenue $ 608 $ 544 |
ORGANIZATION AND DESCRIPTION _2
ORGANIZATION AND DESCRIPTION OF BUSINESS - Narrative (Details) $ in Thousands | Feb. 11, 2020USD ($) | May 12, 2021USD ($) | Mar. 31, 2021USD ($)segmentpatent | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) |
Subsidiary, Sale of Stock [Line Items] | |||||
Number of operating segments | segment | 1 | ||||
Accumulated deficit | $ 159,729 | $ 150,906 | |||
Net loss | (8,823) | $ (8,005) | |||
Cash used | (7,800) | ||||
Cash and cash equivalents | 21,589 | 24,968 | |||
Sale of common stock net of offering costs | $ 28,800 | 4,094 | $ 26,460 | ||
At-The-Market Equity Offering | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Sale of common stock net of offering costs | $ 4,200 | $ 11,400 | |||
Subsequent Event | At-The-Market Equity Offering | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Sale of common stock net of offering costs | $ 500 | ||||
IP Portfolio | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Number of developed technology patents | patent | 320 | ||||
IP Portfolio, XBAR Technology | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Number of developed technology patents | patent | 165 |
SUMMARY OF SIGNIFICANT ACCOUN_3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) | 3 Months Ended | |
Mar. 31, 2021USD ($)financialInstitution | Dec. 31, 2020USD ($) | |
Restricted Cash | ||
Restricted cash | $ | $ 105,000 | $ 105,000 |
Allowance for doubtful accounts | $ | $ 0 | 0 |
Minimum | ||
Debt Instrument [Line Items] | ||
Amortization of Royalty or Other Design Development Fee, Period | 12 months | |
Property and Equipment | ||
Useful life (in years) | 2 years | |
Income Taxes | ||
Completed design license term | 2 years | |
Maximum | ||
Debt Instrument [Line Items] | ||
Amortization of Royalty or Other Design Development Fee, Period | 18 months | |
Property and Equipment | ||
Useful life (in years) | 5 years | |
Income Taxes | ||
Sales-based royalties, period in which payment is due | 30 days | |
Letter of Credit | ||
Restricted Cash | ||
Letter of credit annual step down | $ | $ 50,000 | $ 50,000 |
United States | ||
Concentration Risks, Types, No Concentration Percentage | ||
Number of financial institutions where the company holds checking deposits | financialInstitution | 1 | |
Switzerland | Subsidiaries | ||
Concentration Risks, Types, No Concentration Percentage | ||
Number of financial institutions where the company holds checking deposits | financialInstitution | 1 | |
South Korea | ||
Concentration Risks, Types, No Concentration Percentage | ||
Number of financial institutions where the company holds checking deposits | financialInstitution | 1 |
REVENUE RECOGNITION - Schedule
REVENUE RECOGNITION - Schedule of Changes in Contract Asset and Liability Balances (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Contract liabilities | ||
Contract liabilities, beginning | $ 1,783 | $ 1,731 |
Recognition of revenue included in beginning of year contract liabilities | (592) | (537) |
Contract liabilities, net of revenue recognized on contracts during the period | 104 | 275 |
Contract liabilities, ending | $ 1,295 | $ 1,469 |
REVENUE RECOGNITION - Narrative
REVENUE RECOGNITION - Narrative (Details) $ in Thousands | Sep. 30, 2019USD ($)specific_radio_frequency | Sep. 30, 2020USD ($) | Oct. 31, 2019USD ($) | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) |
Disaggregation of Revenue [Line Items] | |||||
Revenue from collaboration agreement | $ 608 | $ 544 | |||
Proprietary Circuit Designs using XBAR Technology | Murata Manufacturing Co., Ltd. | |||||
Disaggregation of Revenue [Line Items] | |||||
Number of licensed specific radio frequencies | specific_radio_frequency | 4 | ||||
Prepaid royalties | $ 9,000 | ||||
Written termination period | 30 days | ||||
Contracted exclusivity period | 30 months | ||||
Revenue from collaboration agreement | $ 2,500 | $ 500 | $ 500 | ||
Proprietary Circuit Designs using XBAR Technology | Accounts Receivable | Murata Manufacturing Co., Ltd. | |||||
Disaggregation of Revenue [Line Items] | |||||
Revenue from collaboration agreement | $ 2,000 |
WARRANTS - Warrant Share Activi
WARRANTS - Warrant Share Activity (Details) - Common stock warrants | 3 Months Ended |
Mar. 31, 2020$ / sharesshares | |
Roll forward of warrant activity | |
Balance at the beginning of the period (in warrants) | 2,134,362 |
Warrants exercised/expired (in warrants) | 0 |
Balance at the end of the period (in warrants) | 2,134,362 |
Consulting Warrants | |
Warrant liabilities | |
Exercise price (in dollars per share) | $ / shares | $ 0.01 |
Roll forward of warrant activity | |
Balance at the beginning of the period (in warrants) | 6,667 |
Warrants exercised/expired (in warrants) | 0 |
Balance at the end of the period (in warrants) | 6,667 |
Financing Warrants | |
Warrant liabilities | |
Exercise price (in dollars per share) | $ / shares | $ 3.35 |
Roll forward of warrant activity | |
Balance at the beginning of the period (in warrants) | 62,530 |
Warrants exercised/expired (in warrants) | 0 |
Balance at the end of the period (in warrants) | 62,530 |
Private Placement Warrants - September 2017 | |
Warrant liabilities | |
Exercise price (in dollars per share) | $ / shares | $ 4.85 |
Roll forward of warrant activity | |
Balance at the beginning of the period (in warrants) | 1,966,319 |
Warrants exercised/expired (in warrants) | 0 |
Balance at the end of the period (in warrants) | 1,966,319 |
Placement Agent Warrants | |
Warrant liabilities | |
Exercise price (in dollars per share) | $ / shares | $ 4.85 |
Roll forward of warrant activity | |
Balance at the beginning of the period (in warrants) | 98,846 |
Warrants exercised/expired (in warrants) | 0 |
Balance at the end of the period (in warrants) | 98,846 |
STOCKHOLDERS' EQUITY AND LOSS_3
STOCKHOLDERS' EQUITY AND LOSS PER SHARE (Details) $ / shares in Units, $ in Thousands | Feb. 11, 2020USD ($)shares | Feb. 10, 2020shares | Feb. 06, 2020$ / sharesshares | Mar. 31, 2021USD ($)vote$ / sharesshares | Mar. 31, 2020USD ($)shares | Dec. 31, 2020USD ($)$ / sharesshares | Aug. 14, 2020USD ($)$ / shares |
Class of Stock [Line Items] | |||||||
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 | |||||
Number of votes | vote | 1 | ||||||
New shares issued (in shares) | 201,000 | ||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | $ 0.001 | |||||
Net proceeds from units issued in the period | $ | $ 28,800 | $ 4,094 | $ 26,460 | ||||
Gross proceeds from the sale of common stock | $ | $ 26,400 | $ 4,220 | $ 28,750 | ||||
Preferred stock, shares authorized (in shares) | 3,000,000 | 3,000,000 | |||||
Loss Per Share | |||||||
Total shares excluded from net loss per share attributable to common stockholders (in shares) | 5,299,703 | 7,113,091 | |||||
Principal Owner | |||||||
Class of Stock [Line Items] | |||||||
New shares issued (in shares) | 134,000 | ||||||
Common stock warrants | |||||||
Loss Per Share | |||||||
Total shares excluded from net loss per share attributable to common stockholders (in shares) | 0 | 2,134,362 | |||||
Common stock options | |||||||
Loss Per Share | |||||||
Total shares excluded from net loss per share attributable to common stockholders (in shares) | 1,036,358 | 1,216,765 | |||||
Number of Restricted Share Units | |||||||
Loss Per Share | |||||||
Total shares excluded from net loss per share attributable to common stockholders (in shares) | 4,263,345 | 3,761,964 | |||||
Underwritten Public Offering | |||||||
Class of Stock [Line Items] | |||||||
New shares issued (in shares) | 19,166,667 | 16,666,667 | |||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | ||||||
Share price (in dollars per share) | $ / shares | $ 1.50 | ||||||
Over-Allotment Option | |||||||
Class of Stock [Line Items] | |||||||
New shares issued (in shares) | 2,500,000 | ||||||
Over-Allotment Option | Common stock options | |||||||
Class of Stock [Line Items] | |||||||
New shares issued (in shares) | 2,500,000 | ||||||
Option to purchase period | 30 days | ||||||
At-The-Market Equity Offering | |||||||
Class of Stock [Line Items] | |||||||
New shares issued (in shares) | 773,900 | 4,609,701 | |||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.001 | ||||||
Share price (in dollars per share) | $ / shares | $ 5.45 | $ 2.48 | |||||
Net proceeds from units issued in the period | $ | $ 4,200 | $ 11,400 | |||||
Gross proceeds from the sale of common stock | $ | 4,100 | $ 11,000 | |||||
Sale of stock, authorized amount | $ | $ 25,000 | ||||||
Remaining authorized amount to be sold | $ | 9,400 | ||||||
Universal Shelf Registration | |||||||
Class of Stock [Line Items] | |||||||
Sale of stock, authorized amount | $ | $ 100,000 |
STOCK-BASED COMPENSATION - Narr
STOCK-BASED COMPENSATION - Narrative (Details) - $ / shares | 1 Months Ended | |||||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2017 | Jun. 30, 2016 | Mar. 31, 2021 | Jan. 31, 2014 | |
Common stock options | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Options outstanding, weighted average exercise price per share (in dollars per share) | $ 4.64 | |||||
Options exercisable, weighted average exercise price per share (in dollars per share) | $ 4.94 | |||||
2014 Omnibus Incentive Plan | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of shares of common stock approved for issuance (in shares) | 14,950,000 | 1,400,000 | ||||
Number of additional shares authorized (in shares) | 5,000,000 | 4,000,000 | 3,250,000 | 1,300,000 | ||
Number of shares available to issue (in shares) | 4,311,407 |
STOCK-BASED COMPENSATION - Stoc
STOCK-BASED COMPENSATION - Stock Option Award Activity (Details) - Common stock options | 3 Months Ended |
Mar. 31, 2021shares | |
Outstanding | |
Outstanding at the beginning of the year (in shares) | 1,140,975 |
Granted (in shares) | 5,000 |
Exercised (in shares) | (104,465) |
Cancelled or expired (in shares) | (5,152) |
Outstanding at the end of the reporting period (in shares) | 1,036,358 |
Exercisable | |
Exercisable at the beginning of the year (in shares) | 955,302 |
Vested (in shares) | 20,817 |
Exercised (in shares) | (104,465) |
Cancelled or expired (in shares) | 0 |
Exercisable at the end of the reporting period (in shares) | 871,654 |
STOCK-BASED COMPENSATION - Rest
STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) - Number of Restricted Share Units | 3 Months Ended |
Mar. 31, 2021shares | |
Number of Restricted Share Units | |
Outstanding at beginning of year (in shares) | 3,038,785 |
Granted (in shares) | 1,434,007 |
Vested (in shares) | (195,000) |
Forfeited (in shares) | (14,447) |
Outstanding at end of year (in shares) | 4,263,345 |
STOCK-BASED COMPENSATION - Sche
STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Allocation of stock-based compensation expense | ||
Stock compensation expense | $ 2,147 | $ 1,379 |
Research and development | ||
Allocation of stock-based compensation expense | ||
Stock compensation expense | 972 | 648 |
Sales, marketing and administration | ||
Allocation of stock-based compensation expense | ||
Stock compensation expense | $ 1,175 | $ 731 |
LEASES - Narrative (Details)
LEASES - Narrative (Details) $ in Thousands | May 01, 2020USD ($)lease | Mar. 31, 2021USD ($)leaserenewal_option | Mar. 31, 2020USD ($) | Dec. 31, 2020USD ($) |
Lessee, Lease, Description [Line Items] | ||||
Number of operating leases | lease | 2 | |||
Number of non-cancelable leases | lease | 2 | |||
Operating lease right-of-use assets | $ 115 | $ 1,857 | $ 2,012 | |
Operating lease, liability | 2,123 | |||
Restricted cash | $ 105 | $ 105 | ||
Number of lease renewal options recognized | renewal_option | 0 | |||
Finance lease, liability | $ 204 | |||
Operating lease, cost | 286 | $ 283 | ||
Cash paid for operating lease liabilities | 192 | 180 | ||
Finance lease right-of-use asset amortization | 10 | 0 | ||
Lease Amendment | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease renewal periods | 3 months | |||
Number of leases amended | lease | 1 | |||
Base rent deferral period | 3 months | |||
Operating expense deferral period | 3 months | |||
Operating lease, liability | $ 115 | |||
Lab Equipment Lease | ||||
Lessee, Lease, Description [Line Items] | ||||
Finance lease term | 60 months | |||
Finance lease interest rate | 5.99% | |||
Finance lease, right-of-use asset | $ 204 | |||
Finance lease, liability | $ 204 | |||
Research and development | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease, cost | 193 | 209 | ||
Finance lease right-of-use asset amortization | 10 | 0 | ||
Sales, marketing and administration expenses | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease, cost | 93 | $ 74 | ||
Letter of Credit | Corporate Headquarters | ||||
Lessee, Lease, Description [Line Items] | ||||
Security deposit | 50 | |||
Operating lease, deposit letter of credit | $ 200 | 105 | ||
Letter of credit annual step down of no default payment | $ 50 | |||
Minimum | Facilities | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease renewal periods | 2 years | |||
Maximum | Facilities | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease renewal periods | 5 years | |||
Maximum | Facilities and Equipment | ||||
Lessee, Lease, Description [Line Items] | ||||
Operating lease term | 12 months |
LEASES - Weighted-Average Remai
LEASES - Weighted-Average Remaining Lease Term (Details) | Mar. 31, 2021 |
Weighted average remaining term (years) | |
Operating leases | 3 years 5 months 1 day |
Finance lease | 4 years 8 months 1 day |
Weighted average discount rate (%) | |
Operating leases | 4.75% |
Finance lease | 5.99% |
LEASES - Maturities of Operatin
LEASES - Maturities of Operating and Financing Lease Liabilities (Details) $ in Thousands | Mar. 31, 2021USD ($) |
Operating Leases | |
April 1, 2021 - December 31, 2021 | $ 584 |
2022 | 586 |
2023 | 584 |
2024 | 544 |
2025 | 0 |
Total minimum lease payments | 2,298 |
Less: imputed interest | (175) |
Total operating lease liabilities | 2,123 |
Finance Lease | |
April 1, 2021 - December 31, 2021 | 38 |
2022 | 50 |
2023 | 50 |
2024 | 50 |
2025 | 46 |
Total minimum lease payments | 234 |
Less: imputed interest | (30) |
Total operating lease liabilities | $ 204 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - Consulting Agreement | 1 Months Ended | 3 Months Ended | ||
Jan. 31, 2021USD ($) | Aug. 31, 2019USD ($)installment | Mar. 31, 2021USD ($) | Mar. 31, 2020USD ($) | |
Related Party Transaction [Line Items] | ||||
Related party advisory services agreement | $ 50,000 | |||
Number of installment payments | installment | 12 | |||
Expenses from transactions with related party | $ 36,500 | $ 36,500 | ||
Director | ||||
Related Party Transaction [Line Items] | ||||
Due to related parties | 4,000 | |||
Sales, marketing and administration | ||||
Related Party Transaction [Line Items] | ||||
Expenses from transactions with related party | 12,500 | 12,500 | ||
Research and development | ||||
Related Party Transaction [Line Items] | ||||
Expenses from transactions with related party | $ 24,000 | $ 24,000 | ||
Restricted stock units | ||||
Related Party Transaction [Line Items] | ||||
Expenses from transactions with related party | $ 100,000 | $ 100,000 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Loss contingency accrual | $ 0 | $ 0 |
Loss in period | $ 0 | $ 0 |
SEGMENTS AND GEOGRAPHIC INFOR_3
SEGMENTS AND GEOGRAPHIC INFORMATION (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021USD ($)segment | Mar. 31, 2020USD ($) | |
Segment Reporting Information [Line Items] | ||
Number of operating segments | segment | 1 | |
Revenues | $ 608 | $ 544 |
Japan | ||
Segment Reporting Information [Line Items] | ||
Revenues | 494 | 501 |
China | ||
Segment Reporting Information [Line Items] | ||
Revenues | 93 | 36 |
Other | ||
Segment Reporting Information [Line Items] | ||
Revenues | $ 21 | $ 7 |